Isolation of bacteriophages against multidrug resistant Acinetobacter baumannii

Hasan Ghajavand, Bahram Nasr Esfahani, Asghar Havaei, Hossein Fazeli, Reyhaneh Jafari, Sharareh Moghim

Abstract


Increasing multiple drug resistant (MDR) strains of Acinetobacter baumannii has aggravated curiosity in development of alternative therapy. Bacteriophages are often considered as alternative agents for controlling A. baumannii infections. In the present study two lytic phages for MDR A. baumannii were isolated and their efficacy and host ranges were evaluated. The phages were isolated from hospital wastewater. Electron microscopy revealed that IsfAB78 might belong to Myoviridae and IsfAB39 to Podoviridae. Initial characterization of phages showed that they have narrow host range and failed to infect relative and non-relative bacteria. Both phages decreased the A. baumannii turbidity significantly, indicating that these isolated phages may be considered as candidates for phage therapy.


Keywords


Phage therapy; Multidrug resistant Acinetobacter baumannii; Bacteriophage

Full Text:

PDF

References


Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN,Bonomo RA. Global challenge of multidrug – resistunat Acinetobacter baumannii. Antimicrob Agent Chemother. 2007,51(10):3471-3348.

Barbolla RE, Centron D, Maimones, Rospide F, Salgueila C, Altclas J, et al. Molecular epidemiology of Acinetobacter baumannii spread in an adult intensive care unit under an endemic setting. Am J Infect Control. 2008;36(6):444-452.

Fagon JY, Chastre J, Domart Y, Trouillet JL, Gibert C. Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis. 1996;23(3):538-542.

Dijkshoorn L, Van Vianen W, Degener JE, Michel MF. Typing of Acinetobacter calcoaceticus strains isolated from hospital patients by cell envelope protein profiles. Epidemiol Infect. 1987;99:659-667.

Joly-Guillou ML. Clinical impact and pathogenicity of Acinetobacter. Clin Microbiol Infect. 2005;11:868-873.

Sulakvelidze A, Alavidze Z, Morris JG Jr. Bacteriophage therapy. Antimicrob Agents Chemother. 2001;45(3):649–659.

McGrath S and van Sinderen D, (editors). bacteriophage: genetics and molecular biology (1st Ed.). Caister Academic Press. 2001. ISBN: 978-1-904455-14-1.

van Helvoor T. Bacteriological and physiological research styles in the early controversy on the nature of the bacteriophage phenomenon. Med Hist. 1992;3:243–270

Clark JR, March JB. Bacteriophages and biotechnology: vaccines, gene therapy and antibacterial. TrendsBiotechnol. 2006; 24(5):212-218.

Forbes BA, Sahm DF, Weissfeld AS. Baily and Scott's diagnostic microbiology. 12th ed. Mosby Elsevier. Texas. 2007;pp: 334-339.

Turton JF, Woodford N, Glover J, Yard S, Kaufman ME, Pitt TL. Idenfication of Acinetobacter baumannii by detection of the blaoxa51 carbapenemase gene intrinsic to this species. J Clin Microbiol. 2006;44(8):2974-2976.

Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Inter J Antimicrob Agents. 2006;27:351-353.

Morovat T, Bahram F, Mohammad E, Setareh S, Mehdi FM. Distribution of different carbapenem resistant clones of Acinetobacter baumannii in Tehran Hospitals. New Microbiologica. 2009;32:265-271.

Clinical laboratory standards institute (CLSI). Performance standards for antimicrobial susceptibility testing: twentieth informational supplement: M100-S20. Clinical laboratory standards institute, Wayne PA: USA. 2012.

Martha RJ Clokie. Bacteriophages methods and protocols, Volume 1. Isolation, characterization, and interactions. Humana Press. 2009; pp:15-55

Lin NT, Chiou PY, Chang KC, Chen LK, Lai MJ: Isolation and characterization of phi AB2: a novel bacteriophage of Acinetobacter baumannii. Res Microbiol. 2010;161:308–314.

Jin J, Li ZJ, Wang SW, Wang SM, Wang SM, et al. Isolation and characterization of ZZ1, a novel lytic phage that infects Acinetobacter baumannii clinical isolates. BMC Microbiol. 2012;12:156.

Haq I, Chaudhry WN, Andleeb S, Qadri I. Isolation and partial characterization of a virulent bacteriophage IHQ1 specific for Aeromonas punctata from stream water. Microb Ecol. 2012;63:954-963.

Barrow PA, Soothill JS. Bacteriophage therapy and prophylaxis: Rediscovery and renewed assessment of potential. Trends Microbiol. 1997,5:268–271.

Carlton RM. Phage therapy: Past history and future prospects. Arch Immunol Ther Exp. 1999;47:267–274.

Ackermann HW, Brochu G, Konjin HPE: Classification of Acinetobacter phages. Arch Virol. 1994; 135(3-4):345–354.

Soothill JS: Treatment of experimental infections of mice with bacteriophages. J Med Microbiol. 1992;37:258–261.

Chibani- Chenoufi S, Bruttin A, Dillmann ML, Brussow H. Phage- host interaction: an ecological perspective. J Bacteriol. 2004;186:3677-3886.

Bergogone Berezin E, Towner KJ. Acinetobacter spp, as nosocomial pathogens: Microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996;9(2):148-165.

Yang HJ, Liang L, Lin SX, Jia SR. Isolation and characterization of a virulent bacteriophage AB1 of Acinetobacter Baumanii. BMC Microbiol. 2010;10:131.

Yele AB, Thawal ND, Sahu PK, Chopade BA. Novel lytic bacteriophage AB7-IBB1 of Acinetobacter baumannii: isolation, characterization and its effect on biofilm. Arc Virol. 2012;157(8):1441-1450.

Lee CN, Tseng TT, Lin JW, Fu YC, Weng SF, Tseng YH. Lytic myophage Abp53 encodes several proteins similar to those encoded by host Acinetobacter baumanii and phage phiKO2. Appl Environ Microbiol. 2011;77(19):6755-6762.

Popova AV, Miakinina VP, Platonov ME, Volozhantsev NV. Molecular characterization of the multidrug-resistant Acinetobacter baumannii strains and assessment of their sensitivity to the phage AP22. Mol Gen MikrobiolVirusol. 2012;4:18-22.


Refbacks

  • There are currently no refbacks.